Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 1, 2011, Pages 32-42

  Börnsen, Lars ^a   Khademi, Mohsen ^b   Olsson, Tomas ^b   Sørensen, Per Soelberg ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarker; CSF; immunology; multiple sclerosis; osteopontin

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; NEOPTERIN; OSTEOPONTIN; PLACEBO; TAU PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICALLY ISOLATED SYNDROME; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN ANALYSIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 78650973099     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510382247     Document Type: Article

References (51)

1. Lassmann H., Brück W. and Lucchinetti CF The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007 ; 17: 210-218.
2. Kutzelnigg A., Lucchinetti CF, Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 ; 128: 2705-2712.
3. Trapp BD and Nave KA Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008 ; 31: 247-269.
4. Holmøy T. and Hestvik AL Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Curr Opin Infect Dis 2008 ; 21: 271-278.
5. Frischer JM, Bramow S., Dal-Bianco A., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009 ; 132: 1175-1189.
6. Mazzali M., Kipari T., Ophascharoensuk V., Wesson JA, Johnson R. and Hughes J. Osteopontin-a molecule for all seasons. QJM 2002 ; 95: 3-13.
7. Wang KX and Denhardt DT Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008 ; 19: 333-345.
8. Ashkar S., Weber GF, Panoutsakopoulou V., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000 ; 287: 860-864.
9. Nau GJ, Guilfoile P., Chupp GL, et al. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Acad Sci U S A 1997 ; 94: 6414-6419.
10. O'Regan AW, Hayden JM and Berman JS Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000 ; 68: 495-502.
11. Shinohara ML, Kim JH, Garcia VA and Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008 ; 29: 68-78.
12. Aspord C., Rome S. and Thivolet C. Early events in islets and pancreatic lymph nodes in autoimmune diabetes. J Autoimmun 2004 ; 23: 27-35.
13. Shin T., Ahn M., Kim H., Kim HM and Matsumoto Y. Increased expression of osteopontin in the heart tissue of Lewis rats with experimental autoimmune myocarditis. J Vet Med Sci 2006 ; 68: 379-382.
14. Xu G., Nie H., Li N., et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005 ; 115: 1060-1067.
15. Wong CK, Lit LC, Tam LS, Li EK and Lam CW Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005 ; 44: 602-606.
16. Sato T., Nakai T., Tamura N., et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005 ; 54: 1254-1262.
17. Chabas D., Baranzini SE, Mitchell D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001 ; 294: 1731-1735.
18. Hur EM, Youssef S., Haws ME, Zhang SY, Sobel RA and Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007 ; 8: 74-83.
19. Murugaiyan G., Mittal A. and Weiner HL Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008 ; 181: 7480-7488.
20. Sinclair C., Mirakhur M., Kirk J., Farrell M. and McQuaid S. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue micro-arrays. Neuropathol Appl Neurobiol 2005 ; 31: 292-303.
21. Vogt MH, Lopatinskaya L., Smits M., Polman CH and Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003 ; 53: 819-822.
22. Vogt MH, Floris S., Killestein J., et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004 ; 155: 155-160.
23. Comabella M., Pericot I., Goertsches R., et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005 ; 158: 231-239.
24. Altinta A., Saruhan-Direskeneli G., Benbir G., Demir M. and Purisa S. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 2009 ; 276: 41-44.
25. Chowdhury SA, Lin J. and Sadiq SA Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008 ; 65: 232-235.
26. Braitch M., Nunan R., Niepel G., Edwards LJ and Constantinescu CS Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol 2008 ; 65: 633-635.
27. Khademi M., Bornsen L., Rafatnia F., et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009 ; 16: 528-536.
28. Sellebjerg F., Frederiksen JL, Nielsen PM and Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998 ; 51: 529-534.
29. Sellebjerg F., Nielsen HS, Frederiksen JL and Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999 ; 52: 1479-1484.
30. Hoffmann G., Wirleitner B. and Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003 ; 52: 313-321.
31. Whitaker JN Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler 1998 ; 4: 16-21.
32. Terzi M., Birinci A., Cetinkaya E. and Onar MK Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007 ; 115: 325-330.
33. Sellebjerg F., Christiansen M., Jensen J. and Frederiksen JL Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 2000 ; 7: 281-289.
34. Sellebjerg F., Jensen CV, Larsson HB and Frederiksen JL Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler 2003 ; 9: 102-107.
35. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988 ; 38: 180-185.
36. Khademi M., Bornsen L., Rafatnia F., et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009 ; 16: 528-536.
37. Kidd D., Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996 ; 60: 15-19. (Pubitemid 26012261)
38. Thompson AJ, Kermode AG, Wicks D., et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991 ; 29: 53-62.
39. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001 ; 50: 646-657.
40. McFarland HF and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007 ; 8: 913-919.
41. Sellebjerg F., Börnsen L., Khademi M., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009 ; 73: 2003-2010.
42. Danilov AI, Andersson M., Bavand N., Wiklund NP, Olsson T. and Brundin L. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 2003 ; 136: 112-118.
43. Bramow S., Frisher J., Laursen H., Koch-Henriksen N. and Lassmann H. Progressive multiple sclerosis: inflammatory demyelination correlates with the rate of clinical progression prior to death. Mult Scler 2009 ; 15: S5 - S29.
44. Zhang Q., Wrana JL and Sodek J. Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a 'silent' second promoter. Eur J Biochem 1992 ; 207: 649-659.
45. Fatherazi S., Matsa-Dunn D., Foster BL, Rutherford RB, Somerman MJ and Presland RB Phosphate regulates osteopontin gene transcription. J Dent Res 2009 ; 88: 39-44.
46. Singh K., Balligand JL, Fischer TA, Smith TW and Kelly RA Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J Biol Chem 1995 ; 270: 28471-28478.
47. Cheng SL, Zhang SF and Avioli LV Expression of bone matrix proteins during dexamethasone-induced mineralization of human bone marrow stromal cells. J Cell Biochem 1996 ; 61: 182-193.
48. Lee M., Na S., Jeon D., Kim H., Choi Y. and Baik M. Induction of osteopontin gene expression during mammary gland involution and effects of glucocorticoid on its expression in mammary epithelial cells. Biosci Biotechnol Biochem 2000 ; 64: 2225-2228.
49. Hakki SS, Nohutcu RM, Hakki EE, Berry JE, Akkaya MS and Somerman MJ Dexamethasone and basic-fibroblast growth factor regulate markers of mineralization in cementoblasts in vitro. J Periodontol 2005 ; 76: 1550-1558.
50. Kirton JP, Wilkinson FL, Canfield AE and Alexander MY Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res 2006 ; 98: 1264-1272.
51. Weiner HL The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease ? Ann Neurol 2009 ; 65: 239-248.